Objective. There is increasing awareness of the potential impact of paternal exposures on pregnancy outcome. In particular this applies to MTX, which is used in low doses for the treatment of RA and other inflammatory diseases. MTX is associated with a specific pattern of malformations in fetuses of exposed women, but there is uncertainty concerning the risk of paternal low-dose MTX. The aim of this study was to investigate whether paternal low-dose MTX therapy around conception has an unfavourable effect on pregnancy outcome.
Introduction
Several studies analysing drug use among fathers before and during pregnancy have been published [1, 2] . Others have reported on general aspects of counselling paternal exposures [3, 4] , showing the increasing awareness of paternal exposure on pregnancy outcome. However, detailed information is still scarce.
The folic acid antagonist MTX is a cytotoxic drug that is used for malignancies, a variety of rheumatic and inflammatory diseases and termination of pregnancy. Depending on the treatment indication, dosages vary from low doses of 2.530 mg/week to a single dose of 1000 mg/m 2 body surface area for certain cancer types.
MTX is known as a teratogen that causes a specific embryopathy after maternal exposure. This mainly applies to pregnancies after failed attempted termination [5] , but has rarely been described after maternal low-dose therapy for rheumatic disorders [6] . There are concerns that paternal MTX treatment might also interfere with prenatal development. Recently an international panel of rheumatologists recommended stopping MTX at least 3 months before planned pregnancy in both men and women [7] . The impact of paternal MTX and other cytotoxic drugs on fertility resulting in (reversible) azoospermia or oligospermia has been described after cancer therapy [8, 9] . However, information concerning the risk of paternal lowdose MTX on pregnancy outcome is scarce. So far, an overall favourable outcome has been reported by case reports [10, 11] and a case series with 42 pregnancies fathered by men with MTX treatment [12] .
To assess the risks of pregnancies fathered by men on low-dose MTX, we performed a prospective observational study. Objectives were to evaluate the risk of spontaneous abortion (SAB), major birth defects, elective termination of pregnancy (ETOP), prematurity and reduced birth weight.
Patients and methods
The sample of pregnancies with paternal MTX exposure and the comparison cohort were drawn from pregnancies identified by our Teratology Information Service (TIS), which offers risk assessment to physicians, other health care professionals and pregnant women who contact this service for consultation concerning pregnancy. The mission and structure of the TIS has been described elsewhere [13] .
The study design was a prospective observational cohort study involving an exposed and a comparison group. Prospective ascertainment indicates that neither the outcome of the pregnancy nor the results of prenatal diagnosis were known at the time of enrolment in either of the cohorts. Due to the observational nature of this study, ethics approval was not required; this study complied with the ethical standards for biomedical research in Germany.
The study group consisted of pregnant women whose partners had been treated with low-dose MTX (430 mg/week) for rheumatic or inflammatory diseases at conception [Week 2 + 0 after last menstrual period (LMP)] or within 3 months prior to conception. The comparison group consisted of pregnancies not exposed to MTX. Exclusion criteria for both cohorts were maternal exposure to major teratogens (acitretin, isotretinoin, mycophenolate, thalidomide, valproic acid, vitamin K antagonists) or major fetotoxicants [angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers when used in the second or third trimester] as well as acute/recent malignancies of mothers or fathers, failed attempted abortion, maternal antiepileptic therapy and maternal rheumatoid/autoimmune diseases. The samples that met the study criteria were drawn from all eligible pregnancies enrolled in our TIS between 1995 and the beginning of 2012. A ratio of exposed to comparison of at least 1:3 was aimed for ( Supplementary Fig. S1 , available at Rheumatology Online).
Via structured questionnaires and phone interviews, the following data were obtained from the mother and/or the involved physicians after informed consent: exposure details; demographics, including maternal age; pregnancy history, including previous number of children with birth defects; pre-pregnancy BMI; exposure to medications both prescription and over the counter, including specific dosages and dates of exposure; use of folic acidcontaining supplements; exposure to tobacco and alcohol; and details regarding the course and outcome of pregnancy. The methodology is described in more detail elsewhere [13] .
Major birth defects were defined as structural abnormalities of medical, surgical or cosmetic relevance, with special attention to malformations indicative of an MTX embryopathy. Birth defects were classified as major or minor by two of the authors (C.W.-S. and C.S.) according to two standard classification systems [14, 15] . The classifications were performed independently and blinded to exposure data. In case of disagreement between the two authors, consensus was achieved through discussion.
Weeks of gestation were calculated from ultrasound during the first trimester or, if not available, from LMP. SAB was defined as spontaneous pregnancy loss of a fetus <500 g (or at <23 weeks after LMP). Gestational age at delivery and birth weight were measured as continuous variables.
Statistical analysis
Exposed and non-exposed individuals were matched according to year of counselling and their propensity score [16] for bias reduction. The propensity score was estimated based on maternal age, previous parities, previous SAB, smoking and alcohol consumption using boosted regression trees [17] . The pool of potential cases for the comparison group consisted of >25 000 prospectively followed pregnancies with complete data regarding these covariates. Missing data in the five covariates of the study group (6 values out of 565; see Table 1 ) were addressed using multiple imputation by chained equation, assuming that the data were missing at random [18] . Ten imputed data sets were generated per outcome. For each imputed data set, propensity scores were estimated. The mean score per outcome was used for matching [19] . Based on the year of counselling and the logit of the propensity score (within a calliper of 0.5), for each case of the study group a pool of suitable comparison cases was generated (on average, about 600 per study case) and up to four comparison cases were sampled without replacement at random. This procedure ensured that propensity scores of the study and comparison group were equally distributed, resulting in balanced maternal characteristics. Random sampling of suitable comparison cases further reduced possible selection bias. With matching, no further adjustment is required. Instead, results can be compared directly, mimicking a randomized controlled trial.
The risk of SAB was assessed using event history analysis, accounting for competing risks and left truncation due to varying time in gestation of enrolment [20] . The estimation of cumulative incidences was conditional on survival to week 6. Hazard ratios (HRs) were determined using Cox proportional hazards models. Similarly, Cox proportional hazards modelling was used to examine gestational age, taking into account delayed entry.
Birth defect rates were calculated by dividing the number of children/fetuses with birth defects by the number of all live-born infants plus the number of pregnancy losses and terminations with birth defects. Genetic disorders were considered separately. To assess the effect of MTX on the risk of major birth defects, chi-squared tests were used. Due to propensity score matching, no adjustments were required. All analyses were performed using R version 2.15 (R Development Core Team).
Results
Follow-up of pregnancy outcome after paternal low-dose MTX exposure was initiated in 147 cases and completed in 134 (91%). In 7 of the 13 cases lost to follow-up the physician stated that he/she lost contact with the patient, in 5 our institute could not reach the patient and 1 patient refused to answer. According to the study protocol, 16 cases were excluded because paternal therapy was stopped earlier than 3 months pre-conception, 1 because treatment started beyond the first trimester, 1 because of unknown exposure time, 2 because of maternal antiepileptic medication and 1 was a duplicate.
In total, 113 pregnancies of 111 women were included in this study. In 19 pregnancies paternal MTX exposure was limited to the pre-conception window and in 94 pregnancies treatment lasted until conception or longer (Supplementary Table S1 , available at Rheumatology Online). A total of 412 pregnancies were included in the comparison cohort.
Paternal and maternal characteristics
The most frequent drug treatment indication for paternal MTX was RA in 50% (57/113), followed by psoriasis or PsA (33/113) (Supplementary Table S2, available In the comparison group, cytotoxic paternal medication was not reported in any case. Due to propensity score matching, maternal age, maternal smoking habit, alcohol consumption, previous parities and previous SAB were similar between cohorts (Table 1) . First contact was earlier in the MTX cohort (7.14 vs 8 weeks' gestation). Women of the comparison group had a slightly higher BMI and were better educated. However, information concerning these variables was missing in many cases ( Table 2 gives a summary of pregnancy outcomes of the exposed and non-exposed pregnancies (see also Fig. 1 for the post-conception group). Amniocentesis was performed in 12/113 (10.6%) pregnancies in the MTX cohort, and except for one trisomy 16, no chromosomal aberrations were diagnosed. In the comparison cohort, invasive prenatal diagnostics were done in 36/412 (8.7%) pregnancies (35 amniocenteses and 1 chorionic villus biopsy). Two fetuses with trisomy 18 and two familial cytogenetically balanced chromosomal rearrangements [46, XY, t(1;6) mat and 46, XX, inv(2) pat] were observed.
The cumulative incidence of SAB in the exposed cohort (21.4%, 95% CI 13.4, 33.2) did not differ significantly from the comparison cohort (22.4, 95% CI 16.0, 30.8); see Fig. 2 . The HR was 1.19 (95% CI 0.65, 2.17). The cumulative incidence of ETOP was 13.4% (95% CI 7.5, 23.3) in the exposed group and 8.5% (95% CI 5.2, 13.7) in the non-exposed group. However, the difference was not significant (HR 1.69, 95% CI 0.81, 3.51). Of note, the increased cumulative incidence of ETOP in the exposed group influenced the HR for SAB. The cumulative incidence of live births was 65.2% (95% CI 54.4, 75.8) and 69.1% (95% CI 61.5, 76.4) in the exposed and nonexposed groups, respectively.
For child characteristics, see Table 3 . Although there were more preterm infants in the comparison group (15.1% vs 9.2%), there was no significant difference in the gestational age at delivery (HR 0.94, 95% CI 0.74, 1.19) . The children's weight, length and head circumference were all comparable.
Birth defects
For rates of birth defects, see Table 4 . The rate of birth defects did not differ significantly between groups. This is true for all birth defects (OR 0.97, 95% CI 0.40, 2.4), for major birth defects (OR 1.02, 95% CI 0. 16, 6 .57) and for de novo chromosomal aberrations (OR 2.06, 95% CI 0. 27, 15.8) . A detailed overview of all observed birth defects of the exposed group is presented in Supplementary Table S3, available at Rheumatology Online. Furthermore, the observed birth defects were not at all indicative of MTX embryopathy. For major birth defects and chromosomal aberrations of the comparison group, see Supplementary Table S4 , available at Rheumatology Online.
Discussion
Our study covering 113 prospectively ascertained pregnancies fathered by men on low-dose MTX did not reveal an increased risk of adverse pregnancy outcome. This applies not only to the minority of 19 pregnancies with exposure ending before conception, but also to those with therapy until conception and beyond.
Our results are in accordance with a French prospective case series [12] of 36 live births where no congenital malformations were observed. Furthermore, there were no malformations in a small case series of seven infants whose fathers had taken MTX in the periconception period [4] . However, in an analysis of Norwegian health registries, 2 children with orofacial malformations were found among 50 children whose fathers had been dispensed MTX for rheumatic disorders in the period 03 months prior to pregnancy [21] . Altered sex ratio has been debated in context with paternal exposure [22] . Although there were slight differences in our study (Table 3) , these were not significant (OR 1.13, 95% CI 0.70, 1.80; chi-squared test) and the ratio in the MTX cohort is in line with the general population.
Although the risk of SAB in our study was not significantly different between cohorts, the observed cumulative incidences of 21.4% and 22.4% are greater than the generally expected crude background rate of 1116% [2328]. Our approach calculating cumulative incidence rates might better reflect the true abortion risk [20] . Since maternal age is associated with a higher abortion risk [26, 29, 30] , the relatively older age in the exposed and control cohort (median 32.5 and 33 years) might have contributed to our results. An additional influence may have been selection of high-risk women in our cohorts with respect to the number of previous miscarriages and the fact that patients seeking advice at our institute are more severely ill and take more risky drugs than the average pregnant population.
Fear of paternal medication might explain the observed increase (although not significant) of electively terminated pregnancies in the exposed cohort. Different potential mechanisms of paternal reproductive toxicity, including genetic and epigenetic pathways, have been discussed [3, 4, 22] . Mutation of germ cells, induction of germ-line genomic instability and suppression of germ cell apoptosis or interference with genomic imprinting might result in abnormal pregnancy outcome [22] . Furthermore, paternal drugs might act as teratogens after transfer to the embryo via seminal fluids. In humans, seminal fluid does not gain direct access to the uterine cavity; the mechanism of transfer of drugs in seminal fluid is absorption from the vagina [31] . However, the latter aspect has never been shown to be relevant in terms of teratogenicity. To our knowledge, there are no published data on concentrations of MTX in seminal fluid. However, some teratogens such as thalidomide or finasteride were measured in seminal fluid in very small amounts not expected to cause teratogenic effects [32, 33] .
In summary, our study on paternal low-dose MTX did not reveal an increased risk of major malformations, not even in those 32 children whose fathers were treated during the whole organogenesis with a potential direct effect on the developing embryo via MTX-contaminated seminal fluid. However, despite these reassuring results, our study sample is too small to exclude any paternal effects on the fetus, including malformations and genetic disorders. It is important to note that the sample size was sufficient to detect only a threefold increase in risk of major birth defects, given a baseline risk of 3% with a power of $80%. It has been discussed whether amniocentesis should be recommended after paternal MTX therapy, as has been debated with other potentially harmful drugs such as colchicine [34] . So far, there is no evidence to recommend primary invasive diagnostics, considering the risks of amniocentesis or chorionic villus sampling, even though they are very small.
A clear limitation of our study is that we have no information on the father's age, smoking, alcohol consumption, illicit drug use and occupational exposures. These factors might play a role in the origin of some congenital defects [35] , even though it is generally accepted that the influence of maternal effects on pregnancy outcome is much greater.
The strengths and limitations of prospective observational pregnancy outcome studies based on TIS data have recently been discussed in detail [13] . Although this is the largest study published to date on paternal low-dose MTX, the sample size is still too small and follow-up duration too short to give detailed answers to all objectives. In particular, our data do not allow evaluation of the rate of preclinical pregnancy losses as a potential effect of MTX toxicity. Although we cannot completely rule out any bias, the prospective approach of our study with similar procedures of data ascertainment across cohorts makes a substantial bias of exposure and outcome data unlikely.
In conclusion, although the present study has limited power, our data do not provide evidence for an increased risk of adverse pregnancy outcome after paternal low-dose MTX. A 3-month MTX-free interval prior to conception may not be necessary. In the case of unavoidable paternal therapy, it seems reasonable not to postpone family planning. Neither amniocentesis nor the use of condoms during pregnancy seems to be necessary in the case of paternal low-dose MTX therapy.
Rheumatology key messages
. There was no increased rate of birth defects after paternal low-dose MTX around conception. . The spontaneous abortion rate after paternal MTX was not increased. . A 3-month paternal MTX-free interval prior to conception may not be necessary.
